Genes in the service of therapeutic index: Progress for virus-directed enzyme prodrug therapy

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1535-1537

  Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; E1B PROTEIN; ENZYME; ONYX 015; PRODRUG; PROTEIN P53; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5-(1-AZIRIDINYL)-2,4-DINITROBENZAMIDE; AZIRIDINE DERIVATIVE; NITROREDUCTASE;

BIRD DISEASE; CANCER; CELL DEATH; EDITORIAL; GENE THERAPY; GLIOMA; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TUMOR CELL; VIRUS; VIRUS REPLICATION; CLINICAL TRIAL; DNA ADDUCT; ENZYMOLOGY; ESCHERICHIA COLI; GENETIC ENGINEERING; GENETICS; NEOPLASM; NOTE; RNA VIRUS; VIROLOGY;

AZIRIDINES; CLINICAL TRIALS; DNA ADDUCTS; ESCHERICHIA COLI; GENE THERAPY; GENETIC ENGINEERING; HUMANS; NEOPLASMS; NITROREDUCTASES; PRODRUGS; RNA VIRUSES;

EID: 2442700595     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.921     Document Type: Editorial

References (16)

1. Raper SE, Chirmale N, Lee FS, et al: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-158, 2003
2. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al: A serious adverse event after successful gene therapy for X-linked severe combined immuno-deficiency. N Engl J Med 348:255-256, 2003
3. Kirn D: Oncolytic virotherapy for cancer with the adenovirus dl1520(Onyx-015): Results of phase I and phase II trials. Expert Opin Biol Ther 1:525-538, 2001
4. Makower D, Rozenblit A, Kaufman H, et al: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 9:693-702, 2003
5. ARF tumor suppressor genes. J Virol 76:12483-12490, 2002
6. Pecora AL, Rizvi N, Cohen GI, et al: Phase I trial of intravenous administration of PW01, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20:2251-2266, 2002
7. Shah A, Benos D, Gillespie GY, et al: Oncolytic viruses: Clinical applications as vectors for the treatment of gliomas. J Neurooncol 65:203-226, 2003
8. Gromeier M, Lachmann S, Rosenfeld MR, et al: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97:6803-6808, 2000
9. Russell SJ: RNA viruses as virotherapy agents. Cancer Gene Ther 9:961-966, 2002
10. Boyd D, Hung CF, Wu TC: DNA vaccines for cancer. IDrugs 6:1155-1164, 2003
11. Ribas A, Butterfield LH, Glaspy JA, et al: Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415-2432, 2003
12. Kirn D, Niculescu-Duvaz I, Hallden G, et al: The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 8:s68-73, 2002 (suppl 4)
13. Palmer DH, Mautner V, Mirza D, et al: Virus directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 22:1546-1552, 2004
14. Chung-Faye G, Palmer D, Anderson D, et al: Virus-directed enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7:2662-2668, 2001
15. Pedley RB, Sharma SK, Hawkins RE, et al: Antibody-directed enzyme prodrug therapy. Methods Mol Med 90:491-514, 2004
16. Freytag SO, Stricker H, Pegg J, et al: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional confocal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63:7497-7506, 2003